Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586477 | 0.96 | MEN1 (0.54) | MEN1KMT2ATSHRALDH1A1USP2 | |
| Fumaric Acid SCHEMBL10499414 | 0.90 | TSHR (0.51) | MEN1KMT2ATSHRALDH1A1USP2 | |
| Fumaric Acid SCHEMBL10499430 | 0.90 | TSHR (0.51) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL10498885 | 0.88 | MEN1 (0.61) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL10498575 | 0.88 | MEN1 (0.72) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL10499011 | 0.87 | MEN1 (0.63) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL10499179 | 0.86 | MEN1 (0.61) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL9636375 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL9687118 | 0.85 | MEN1 (0.42) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL10498573 | 0.85 | KDM4E (0.74) | MEN1KMT2ATSHRALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0123962-B1 | BENZIMIDAZOLE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION | KANEBO, LTD. (JP) | 1989-12-27 | — | — | EP | claimed |
| US-4603130-A | ANTIHISTAMINES | KANEBO, LTD. (JP) | 1986-07-29 | — | — | US | claimed |
| EP-0123962-A2 | Benzimidazole derivative, process for the preparation thereof and pharmaceutical composition | KANEBO, LTD. (JP) | 1984-11-07 | — | — | EP | claimed |
| JP-59199679-A | — | — | None | — | — | JP | disclosed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| EP-0957100-B1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | KOWA CO (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
| US-6127360-A | ANTIHISTAMINES, ANTILEUKOTRIENES, ANTIINFLAMMATORY AGENTS, ANTIASTHMATIC AGENTS | KOWA CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0957100-A1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0123962-B1 | BENZIMIDAZOLE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION | KANEBO, LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-4603130-A | ANTIHISTAMINES | KANEBO, LTD. (JP) | 1986-07-29 | — | — | US | disclosed |
| JP-S59199679-A | NOVEL BENZIMIDAZOLE DERIVATIVE, ITS PREPARATION AND MEDICINAL COMPOSITION CONTAINING THE SAME | KANEBO LTD | 1984-11-12 | — | — | JP | disclosed |
| EP-0123962-A2 | Benzimidazole derivative, process for the preparation thereof and pharmaceutical composition | KANEBO, LTD. (JP) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | MEN1 3799/4885KMT2A 2271/4885TSHR 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.